Lithium is the mainstay treatment in bipolar disorder (BD) for its effectiveness in the acute phases of illness and in prevention of recurrences. Lithium's mechanism of action is complex, and while it modulates the function of hundreds of molecular targets, most of these effects could be unspecific and not relevant for its clinical efficacy. In this study, we applied an integrated analytical approach using genome-wide expression and genotyping data from BD patients to identify lithium-responsive genes that may serve as biomarkers of its efficacy. To this purpose, we tested the effect of treatment with lithium chloride 1 mM on the transcriptome of lymphoblasts from 10 lithium responders (LR) and 10 nonresponders (NR) patients and identified genes significantly influenced by the treatment exclusively in LR. These findings were integrated with gene-based analysis on genome-wide genotyping data from an extended sample of 205 BD patients characterized for lithium response. The expression of 29 genes was significantly changed by lithium exclusively in LR. Gene-based analysis showed that two of these genes, zinc finger protein 429 (ZNF429) and zinc finger protein 493 (ZNF493), were also significantly associated with lithium response. Validation with quantitative real-time polymerase chain reaction confirmed the lithium-induced downregulation of ZNF493 in LR (p = .036). Using convergent analyses of genome-wide expression and genotyping data, we identified ZNF493 as a potential lithium-responsive target that may be involved in modulating lithium efficacy in BD. To our knowledge, this is the first evidence supporting the involvement of zinc finger proteins in lithium response.
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| INTRODUCTION
Lithium has been used for more than 70 years in the management of bipolar disorder (BD) for its effectiveness in the acute phases of illness (manic and depressive) and in the prevention of manic and depressive recurrences (Gitlin & Frye, 2012; Malhi, Tanious, Das, & Berk, 2012) .
Response to lithium is highly variable, and although 30% of patients under chronic treatment are excellent responders, 70% show partial or no response (Grof et al., 2002) . Part of this variability is explained by genetic variance, as also suggested by the evidence that lithium response is heritable (Grof et al., 2002) . However, the complexity of lithium's mechanism of action has hampered our understanding of the molecular networks involved in its clinical efficacy. Lithium has been shown to influence multiple molecular processes, including ion transport, neurotransmitter signaling, neuronal survival, and many others.
Nevertheless, the majority of these molecular modifications appear to be unrelated to its clinical effects (Alda, 2015) . In this respect, the management of therapeutic intervention, side effects, and toxicity would greatly benefit from the identification of biomarkers of response (McKnight et al., 2012) .
Recently, findings from the largest genome-wide association (GWA) study conducted by the International Consortium on Lithium Genetics (ConLiGen) suggested the involvement of two noncoding RNA (lncRNA) genes in lithium response (Hou et al., 2016) . This result is promising and with potentially high impact, but further exploration using different molecular techniques and possibly animal models is warranted. GWA allow exploring the genome for genetic variants associated with the phenotypic trait, but their power is limited in that the function of many variants is not known. Conversely, transcriptomic studies allow investigating the role of differentially expressed genes in the phenotype under study. To this regard, deeper and more detailed information on the genetics of lithium response would be provided by the integration of data from multiple genome-wide datasets (Hunsberger et al., 2015; Niculescu 3rd & Kelsoe, 2001 ).
Recently, Witt et al. (2014) applied a convergent approach to identify new candidate genes for BD. In this study, combination of GWA and genome-wide gene expression (GWGE) data measured during euthymic and manic state identified Stabilin 1 gene (STAB1) as a potential trait marker of BD (Witt et al., 2014) . Another study recently compared microRNA (miRNA) and messenger RNA (mRNA) profiling in lymphoblastoid cell lines (LCLs) derived from BD patients characterized for lithium response (Hunsberger et al., 2015) to construct treatment specific gene regulatory networks, suggesting that the Let-7 family of miRNAs could be involved in modulating lithium response.
These studies support the notion that convergent approaches could constitute powerful tools to identify genes and pathways involved in lithium response and possibly in its mechanism of action.
Here, we present findings from the first study to date using genome-wide genotyping and genome-wide expression profiles from a sample of BD patients characterized for lithium response, with the aim of identifying lithium-regulated genes possibly involved in its clinical efficacy.
| MATERIALS AND METHODS

| Sampling and genotyping
A study flow diagram is reported in Figure 1 (Squassina et al., 2016) . Briefly, the sample included 140 female and 65 male patients (mean age at sampling, years AE standard deviation [SD] : 47.9 AE 14.5) with a diagnosis of BD type I (n = 154) or BD type II (n = 51), based on research diagnostic criteria (Spitzer, Endicott, & Robins, 1978) Grof et al., 2002; Manchia et al., 2013) . Our sample included 59 LR and 146 nonresponders (NR).
The research protocol followed the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the University of Cagliari, Italy. All participants signed informed written consent after a detailed description of the study procedures.
DNA was extracted from peripheral blood samples. The sample is part of the ConLiGen (Hou et al., 2016; Schulze et al., 2010) , and genome-wide genotyping was carried out at the National Institute of Mental Health (Bethesda, MD), with Illumina 2.5M Omni Chip arrays according to the manufacturers' protocols.
| Genome-wide gene expression
For the genome-wide expression study, we selected 10 patients who showed excellent response to lithium (TS ≥ 8) and 10 NR (TS = 0) from the genotyped sample. Details on selection criteria and experimental procedures were described elsewhere (Squassina et al., 2013 ).
All patients included in this sample had a diagnosis of BD type I. LR and NR did not differ for sex (M/F, LR: 5/5; NR: 4/6), age at sampling (years AE SD, LR: 46.6 AE 17.5; NR: 40.7 AE 10.0, Mann-Whitney test p value = ns) or years of frozen storage of LCLs (years AE SD, LR: 8.8 AE 4.7; NR: 13.1 AE 5.2, Mann-Whitney test p value = ns).
Briefly, Epstein-Barr virus immortalized LCLs were established from lymphocytes collected from each patient when enrolled in our molecular studies and stored in liquid nitrogen (Neitzel, 1986) . At the time of the experiments, LCLs were thawed and cultured using a standard protocol previously described (Squassina et al., 2013) . Once LCLs reached the required cell count (6-9 × 10 6 cells), two equivalent aliquots were transferred into separate flasks. One aliquot was cultured with medium supplemented with 1 mM lithium chloride (LiCl), while the other one was cultured with drug-free medium, under identical conditions. After 7 days of treatment, cells were harvested for RNA extraction using TRI reagent solution (Ambion, Austin, TX). The quality of RNA was considered to be adequate when the A 260 /A 280 ratio assessed using a NanoDrop ND-1000 spectrophotometer was in the range of 1.8-2.0, and the RNA integrity number assessed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) was in the range of 7-10. and 45 cycles at 95 C for 15 s and 60 C for 1 min. qRT-PCR experiments were run in triplicate using the TaqMan assays "on demand"
Hs03007122_m1 and Hs00703379_s1 (ThermoFisher Scientific) in a
StepOnePlus instrument (Applied Biosystems). Target genes were normalized using Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
as a housekeeping gene.
| Statistical analysis 2.4.1 | Genotyping and gene-based analysis
Quality control of GWA data was performed with PLINK v. 1.09 (Purcell et al., 2007) . 
| Genome-wide gene expression
GeneChip data quality control was performed using Expression Console Software (Affymetrix). Transcriptome data were normalized using the Robust Multi-array Average algorithm (Irizarry et al., 2003) and duplicated or missing Entrez IDs were removed. Genes were tested for differential expression after in vitro lithium treatment in both LR and NR using the paired t test implemented in limma (Smyth, 2004) . Based on findings from our previous work (Squassina et al., 2013) , suggesting that LiCl in vitro has a small-medium effect on gene expression modifications in LCLs, significance was defined based on a less stringent false discovery rate (FDR) threshold of 20%. This threshold allowed us to include the largest possible number of genes at this step at the same time guaranteeing to reach 80% power to identify a differential expression with a medium effect size (Cohen's dz = 0.7). 
| Integration of expression and gene-based data
Gene-based analysis on the GWA dataset was run to check for further evidence on the involvement in lithium response of genes showing LiCl-induced differential expression in LR (n = 29). Gene-based statistics was computed by MAGMA and a Bonferroni corrected threshold was calculated based on the number of genes of interest (Bonferroni p = .0017; nominal p = .05/number of genes = 29).
| Validation with qRT-PCR
Genes for validation with qRT-PCR were selected among those showing significantly differential expression after lithium treatment in LR but not in NR and association with lithium response in the gene-based analysis performed on the genotyping data. Relative expression levels
were measured with the comparative Ct method (ΔΔCt) using GAPDH as the endogenous reference and an external control as the calibrator.
Differences between baseline and lithium-treated samples were analyzed using the paired t test. The significance threshold was set at p < .05. Statistical tests were carried out using SPSS statistical software package v20 (SPSS, Inc., Chicago, IL) and GraphPad Prism v. 5.00
(GraphPad Software, San Diego, CA).
| RESULTS
Analyses of genome-wide expression data showed that lithium altered the expression of 33 genes in LR and 15 genes in NR with FDR < 20%. Four genes were modified by lithium in both groups and were excluded from subsequent analyses. In total, 29 genes were altered by lithium exclusively in LR (Table 1) : 17 genes were downregulated and 12 upregulated.
In the GWA analysis, after quality control, a total of 197 patients 
| DISCUSSION
Using data from GWGE and genotyping, our study shows for the first time that zinc finger proteins could be involved in modulating lithium response. Zinc finger proteins are a large group of small functional domains (23-28 amino acids) that contain multiple residues of cysteine (Cys) and/or histidine (His) and require one or more zinc ions to stabilize their structure (Laity, Lee, & Wright, 2001; Wolfe, Nekludova, & Pabo, 2000) . These domains are abundant in eukaryotic genomes and are involved in several functions including transcriptional activation, regulation of apoptosis, and protein folding (Laity et al., 2001) . Zinc finger proteins are classified in different families on the basis of the number and order of Cys/His residues, for example, Cys2His2, Cys4, and Cys6 (Sun et al., 2015; Wolfe et al., 2000) .
Domains containing the Cys2His2 residues are the most represented.
These proteins bind to major groove of the DNA and are involved in transcriptional regulation (Sun et al., 2015; Wolfe et al., 2000) . Both ZNF429 and ZNF493 codify for Cys2His2 zinc finger proteins according to public databases (UniProtKB/Swiss-Prot). Although a possible role of these specific genes in BD has not been suggested yet, another member of the Cys2His2 zinc finger class, zinc finger protein 804A (ZNF804A), was recently associated with BD and schizophrenia (Williams et al., 2011; Zhang et al., 2011; Zhang et al., 2016) . As for ZNF429 and ZNF493, the role of ZNF804A is not well characterized.
However, a recent study using a gene knockdown approach in neural progenitor cells suggested ZNF804A to be involved in modulation of transcription of a large number of genes (Chen et al., 2015) . Specifically, this study showed that genes involved in interferon-signaling Note. Linear FCs were calculated as FC = 2^logFC using the estimates of the log2-fold change corresponding to the effect of lithium treatment provided by limma. The significance threshold was set at q < 0.2 at this step. Genes reported in bold were also found to be associated with lithium response in the genotyped dataset. CI = confidence interval; FC = fold change.
were significantly enriched among those that were downregulated after ZNF804A knockdown, suggesting that this gene might be able to impact response to inflammatory cytokines. Much less is known about ZNF429 and ZNF493. Both genes are located at 19p12, a region previously associated with telomere homeostasis in humans (Mangino et al., 2012) . Specifically, the genetic variant rs412658, that is located near zinc finger protein 676 (ZNF676), has been associated with telomere variation (Mangino et al., 2012) . Although the mechanism through which ZNF676 could impact telomere variation is not known, zinc finger proteins could either modulate the expression of genes involved in telomere maintenance through their interaction with DNA or influence the posttranslational expression of a gene via binding with RNA or proteins (Mangino et al., 2012) . Moreover, zinc finger proteins can stabilize the G-quadruplex structure formed by telomeric DNA (Isalan, Patel, Balasubramanian, & Choo, 2001; Ladame et al., 2006; Mangino et al., 2012 ) and engineered zinc fingers are able to inhibit human telomerase activity (Patel et al., 2004) . A recent preclinical study reported intriguing results supporting the role of another member of the zinc finger protein family, zinc finger protein 637 (Zfp637), in telomere maintenance (Gao et al., 2014) . In this study, the endogenous expression levels of Zfp637 and mouse telomerase reverse transcriptase (mTERT) were found to be downregulated during oxidative stress-induced premature senescence.
Conversely, overexpression of Zfp637 was found to increase telomerase activity and reduction of oxidative stress via binding to the mTERT promoter (Gao et al., 2014) . Interestingly, several studies suggest that lithium might normalize telomere dysfunction (Martinsson et al., 2013; Squassina et al., 2016; Squassina et al., 2017; Wei, Backlund, Wegener, Mathe, & Lavebratt, 2015) , although the exact mechanisms are not known. It could be speculated that the impact that lithium could exert on telomere length could be partly mediated by its action on zinc finger proteins. However, to date no evidence is available to support this hypothesis. As no previous study reported a possible role of ZNF429 and ZNF493 in lithium's mechanism of action, further investigation is required to confirm and extend our findings.
Our results should be interpreted in light of their limitations. First, the sample size of this study likely provided us a limited statistical power to detect small effect sizes. Due to the small-medium effect of LiCl on the modulation of gene expression in LCLs, as suggested by our previous work (Squassina et al., 2013) , we decided to relax the FDR threshold to 20% in the transcriptome analysis. While this approach allowed us to increase the number of genes based on which we generated a hypothesis that we then validated in the further steps of this study, this approach also increased the chance of false 
